VVN461

VVN461 is a non-steroidal, small-molecule dual inhibitor of **Janus kinase 1 (JAK1)** and **Tyrosine kinase 2 (TYK2)** developed by **VivaVision Biotech**. Formulated as an ophthalmic solution (eye drops), it is designed to treat various ocular inflammatory conditions, including **non-infectious anterior uveitis** and **post-operative ocular inflammation** following cataract surgery. The drug works by inhibiting the JAK-STAT signaling pathway, which is a key driver of inflammatory cytokine production in ocular tissues. VVN461 is positioned as a potentially safer alternative to topical corticosteroids, aiming to provide potent anti-inflammatory effects without the common steroid-related side effects such as elevated intraocular pressure and accelerated cataract formation. Clinical data has shown VVN461 to be non-inferior to prednisolone acetate in treating uveitis and effective in reducing post-operative inflammation in Phase 2 and Phase 3 trials.